Clinical trial
A Phase 2, Open-Label, Multicenter, 12-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AT1001 in Patients With Fabry Disease
NCT00214500 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Multicenter, 12-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AT1001 in Patients With Fabry Disease
- Lead sponsor
- Amicus Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 2, 2006
- Completion date
- January 29, 2008
- Enrollment
- 9 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.